Myriad Ansoff Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Growth Strategy Behind the Preview
This Myriad Amsoff Matrix Analysis helps you quickly assess growth options across market penetration, market development, product development, and diversification. This page already shows a real preview of the actual report, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Market Penetration
Grow GeneSight use in psychiatry workflows
Myriad Genetics, Inc. can make GeneSight the default pharmacogenomics test in psychiatry and primary care accounts, which fits a recurring use case because medication switches and dose changes happen over time. In 2025, the best gains come from higher reorder rates, faster ordering, and fewer abandoned tests, all inside an installed base, so the risk stays low. That makes GeneSight a practical penetration play: same test, same setting, more repeat use.
Defend myRisk share in hereditary cancer
Myriad Genetics, Inc. can defend myRisk in hereditary cancer by staying inside the first decision point for oncology and women's health clinicians: BRCA and family-history review. Pathogenic BRCA1/2 variants affect about 1 in 400 people overall, and about 1 in 40 people of Ashkenazi Jewish ancestry, so early testing can steer care before treatment plans are set. Better guideline visibility and payer coverage are the main levers to keep myRisk in the pathway.
Increase Foresight and Prequel conversion
Myriad Genetics, Inc. can grow Foresight Carrier Screen and Prequel Prenatal Screen by turning more OB-GYN and maternal-fetal medicine visits into orders, and each pregnancy path can create 2 screening decisions. In 2025, the real lever is workflow, not product reinvention: simpler ordering, faster counseling, and easier specimen collection raise conversion. That matters because prenatal screening is a repeat, high-volume care step, so even a small lift in order rate can add meaningful revenue.
Use payer coverage to expand volume
Myriad Genetics, Inc. can lift volume by making reimbursement steadier across oncology, women's health, and pharmacogenomics. In diagnostics, payer coverage is a direct order signal: when prior auth gets faster, denials fall, and patient out-of-pocket costs ease, clinicians are more likely to test. For Myriad Genetics, Inc., payer access is both a pricing lever and a market penetration lever.
Win with faster turnaround and service quality
Myriad Genetics, Inc. can win more U.S. share by making orders faster, specimen tracking tighter, and clinician support easier to use than rivals. In FY2025, that matters most in oncology and prenatal testing, where small workflow gains can lift conversions because doctors prefer tests that are simple to order and simple to read.
A sharper service model can defend mature markets without cutting price. Faster turnaround and cleaner logistics help Myriad Genetics, Inc. stay sticky with labs and practices that value low friction and high confidence.
Myriad Genetics Grows by Winning More Share in Existing Care Paths
Myriad Genetics, Inc. can grow by taking more share inside the same care paths: GeneSight in psychiatry, myRisk in hereditary cancer, and Foresight Carrier Screen and Prequel Prenatal Screen in OB-GYN visits. In FY2025, the best penetration gains come from repeat orders, faster workflow, and steadier payer coverage, not new products. That keeps growth inside an installed base.
| FY2025 lever | Data |
|---|---|
| BRCA risk | 1 in 400 |
| Ashkenazi Jewish ancestry | 1 in 40 |
| Prenatal decisions | 2 per pregnancy |
What is included in the product
Detailed Word Document
Editable Excel File
Market Development
Move GeneSight into primary care settings
Myriad Genetics, Inc. can widen GeneSight from psychiatry into primary care and integrated delivery networks, which multiplies prescribers who can order it. This fits market development: same test, broader clinical audience.
The need is real, since about 70% of U.S. counties lack a psychiatrist and primary care handles most first-line depression treatment. That makes GeneSight most useful where drug trial-and-error is common and mental-health access is thin.
Expand women's health testing into more channels
Myriad Genetics, Inc. can push Foresight and Prequel into three adjacent channels: fertility clinics, telehealth, and larger OB-GYN networks. These settings already handle reproductive-risk decisions, so the test menu can stay the same while reach widens. The main job is channel education and referral capture, because growth only works if more providers trust and order the tests.
Broaden hereditary cancer reach beyond legacy accounts
Myriad Genetics, Inc. can use myRisk to reach more community oncology groups, survivorship programs, and multispecialty health systems without changing the test, which makes this a clean market development move. About 5% to 10% of cancers are linked to inherited mutations, so family-history review is still underused in many care settings. Wider site-of-care coverage can lift the installed base and bring more eligible patients into the same hereditary cancer workflow.
Build volume through new geographic access points
Myriad Genetics, Inc. can grow by moving beyond its U.S. physician base into new geographies through local partners and distributors. In diagnostics, licensed clinical tests with repeatable workflows often scale faster through allies than a fully owned launch, because local sales, reimbursement, and lab access already exist. That path is slower than U.S. penetration, but it can extend test volume and revenue runway with less upfront spend.
Target employer and health-system populations
Myriad Genetics, Inc. can push its existing tests into employer-sponsored and health-system programs, where buyers want steady use, better risk stratification, and lower downstream costs over 1 to 3 years. This is market development: the same test menu reaches new customer types, so value comes from pathway adoption at scale, not one-off test sales.
Employer plans and health systems manage large covered lives, so even modest adoption can widen test volume and support longer-term contract renewals.
Myriad Genetics Can Expand by Taking Gene Tests to New Buyers
Myriad Genetics, Inc. can grow GeneSight, Foresight, Prequel, and myRisk by selling the same tests to new buyers like primary care, OB-GYN, community oncology, telehealth, and employer health plans. This is market development: same menu, wider use. In 2025, about 70% of U.S. counties still lack a psychiatrist, and only 5% to 10% of cancers are linked to inherited mutations.
| 2025 market cue | Why it matters |
|---|---|
| 70% counties lack psychiatrists | GeneSight can expand into primary care |
| 5% to 10% cancers inherited | myRisk can reach more oncology sites |
Get Your Copy
Myriad Reference Sources
This is the actual Myriad Amsoff Matrix Analysis document you'll receive after purchase – no sample, no placeholders, just the full professional file. The preview you see here is taken directly from the complete document.
Once you complete checkout, you unlock the same detailed Myriad Amsoff Matrix Analysis in full. What you see now is exactly what you'll download, ready for immediate use.
Product Development
Refresh gene panels and interpretation logic
Myriad Genetics, Inc. can keep inherited-risk tests current by refreshing gene panels, tightening variant interpretation, and updating clinical reports. In a fast-moving genetics market, even small panel edits can improve clinical relevance and help protect installed accounts. This kind of product development is incremental, but it is still one of the cheapest ways to defend share and keep pace with new evidence.
Add more decision support around GeneSight
In 2025, Myriad Genetics, Inc. can grow GeneSight through product development by adding better reporting, prescribing guidance, and workflow tools without changing its core market. Clinicians want an actionable result in under 1 visit, so clearer outputs for psychiatrists, primary care doctors, and care coordinators can lift adoption. This fits Ansoff because it deepens value around an existing test, not a new customer segment.
Expand women's health content and risk models
Myriad Genetics, Inc. can widen women's health revenue by adding carrier screening and prenatal risk content to one OB-GYN visit, so one touchpoint can answer 2+ genetic questions. In FY2025, this supports a larger use case inside the same care channel, where providers need faster interpretation and fewer follow-ups. Better counseling tools can cut time per result and lift test adoption without changing the core market.
Develop oncology assays for recurrence risk
Myriad Genetics, Inc. can expand oncology by building assays that estimate recurrence risk, not just inherited risk. That moves the product mix deeper into active cancer care and post-treatment choices, where doctors need a clearer call on who needs escalation and who can avoid more therapy. This is product development because it adds a new assay layer to an existing oncology base.
Create digital layers around the lab menu
Myriad Genetics, Inc. can add digital ordering, reporting, and patient-navigation tools around its lab menu, which fits a product development move in the Ansoff Matrix. In diagnostics, the software layer matters because it cuts drop-off at each step, from order entry to results review, and that can lift completion rates without changing the core assay.
Better digital workflows can also improve clinician satisfaction and make turnaround times easier to use in practice. For Myriad Genetics, Inc., that raises product value in the existing market without needing a new test category.
Myriad Genetics' FY2025 Focus: Smarter Tests, Better Reports, Same Market
Myriad Genetics, Inc.'s product development in FY2025 is about improving existing tests, reports, and digital workflows, not chasing new markets. That matters because clinicians still want faster, clearer calls from one visit, and small upgrades can protect share.
| FY2025 lever | Value |
|---|---|
| Visit depth | 1 visit |
| Use case | 2+ genetic questions |
| Core move | Panel, report, workflow upgrades |
For Myriad Genetics, Inc., this is the cheapest way to raise test value inside the same customer base.
Diversification
Enter companion diagnostics with biopharma partners
Myriad Genetics, Inc. can diversify by pairing companion diagnostics with biopharma partners, because drug developers buy R&D, validation, and launch support, not routine physician workflows. One alliance can run 2 to 5 years and cover test design through commercialization, so the revenue model is less transactional and more partnership-based. In 2025, this use case shift expands Myriad Genetics, Inc. beyond its core clinical testing market.
Move deeper into oncology monitoring
Myriad Genetics, Inc. can move deeper into oncology monitoring by adding tools for treatment response and recurrence surveillance, a step beyond inherited-risk testing into active disease management. That market is adjacent but separate: U.S. cancer cases are expected to top 2.0 million in 2025, so oncologists need repeat monitoring, not just one-time screening. If Myriad Genetics, Inc. proves clinical utility and payer coverage, this can raise share of wallet in a setting where recurrence checks often happen every 3 to 6 months.
Build a broader precision medicine platform
Myriad Genetics, Inc. can broaden beyond test sales by packaging its lab, data, and variant-interpretation work into a precision-medicine platform. In FY2025, that kind of model can serve three buyers at once: providers, biopharma, and payers, while also supporting research, decision support, and evidence generation around genomics. The upside is less dependence on one test line and more repeat revenue from the same diagnostic infrastructure.
That matters because Myriad Genetics, Inc. already has the core assets a platform needs: scale, clinical data, and test interpretation. A broader model can turn each case into more than a one-time sale, especially as U.S. molecular diagnostics continues to grow from a roughly $30 billion base and precision oncology demand stays high.
Expand into adjacent testing services
Myriad Genetics, Inc. can diversify by adding adjacent tests that fit beside hereditary cancer and pharmacogenomic services, using the same physician network to sell a new clinical answer. That lowers dependence on any one test line and can smooth revenue swings when one franchise slows. The best fit is a test that reuses the commercial engine but serves a different medical question, so the incremental sales cost stays low.
Use data partnerships as a second growth engine
Myriad Genetics, Inc. can use data partnerships with health systems, biopharma, and research groups to add a second growth engine beyond testing. That shifts the model from pure diagnostics to testing plus evidence generation and analytics, which can create recurring value for patients, providers, and sponsors. It is harder to run than core testing, but it can widen Myriad Genetics, Inc.'s long-term market far beyond one-off lab orders.
Myriad Genetics Expands Beyond One-Time Testing as Oncology Demand Grows
Myriad Genetics, Inc. can diversify by using its oncology and companion-diagnostic base to sell adjacent tests, data, and evidence services. In 2025, U.S. cancer cases are expected to exceed 2.0 million, so demand for repeat monitoring and treatment guidance stays strong. This lowers reliance on one-off hereditary testing and supports more recurring revenue.
| 2025 signal | Why it matters |
|---|---|
| 2.0M+ U.S. cancer cases | Supports adjacent oncology tests |
Frequently Asked Questions
Myriad Genetics, Inc. uses 4 main levers: stronger payer coverage, better physician education, easier ordering, and repeat use in existing accounts. The goal is to deepen adoption across 3 core franchises: oncology, women's health, and pharmacogenomics. This is the most efficient growth path because it improves conversion, retention, and workflow without requiring a new product category.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.